Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota
Jun Xu
School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong
Search for more papers by this authorCorresponding Author
Hu-Biao Chen
School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong
Correspondence to: S.-L. Li, Jiangsu Province Academy of Traditional Chinese Medicine, Hongshan Road, Nanjing 210028, Jiangsu Province, PR China. E-mail [email protected] or H.-B. Chen, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong. E-mail [email protected]Search for more papers by this authorCorresponding Author
Song-Lin Li
Department of Pharmaceutical Analysis, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028 P.R. China
Department of Metabolomics, Jiangsu Province Academy of Traditional Chinese Medicine and Jiangsu Branch of China Academy of Chinese Medical Sciences, Nanjing, 210028 P.R. China
Correspondence to: S.-L. Li, Jiangsu Province Academy of Traditional Chinese Medicine, Hongshan Road, Nanjing 210028, Jiangsu Province, PR China. E-mail [email protected] or H.-B. Chen, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong. E-mail [email protected]Search for more papers by this authorJun Xu
School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong
Search for more papers by this authorCorresponding Author
Hu-Biao Chen
School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong
Correspondence to: S.-L. Li, Jiangsu Province Academy of Traditional Chinese Medicine, Hongshan Road, Nanjing 210028, Jiangsu Province, PR China. E-mail [email protected] or H.-B. Chen, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong. E-mail [email protected]Search for more papers by this authorCorresponding Author
Song-Lin Li
Department of Pharmaceutical Analysis, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028 P.R. China
Department of Metabolomics, Jiangsu Province Academy of Traditional Chinese Medicine and Jiangsu Branch of China Academy of Chinese Medical Sciences, Nanjing, 210028 P.R. China
Correspondence to: S.-L. Li, Jiangsu Province Academy of Traditional Chinese Medicine, Hongshan Road, Nanjing 210028, Jiangsu Province, PR China. E-mail [email protected] or H.-B. Chen, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong. E-mail [email protected]Search for more papers by this authorContract grant sponsor: National Natural Science Foundation of China; Contract grant number: 81373946.
Abstract
Herbal medicines (HMs) are much appreciated for their significant contribution to human survival and reproduction by remedial and prophylactic management of diseases. Defining the scientific basis of HMs will substantiate their value and promote their modernization. Ever-increasing evidence suggests that gut microbiota plays a crucial role in HM therapy by complicated interplay with HM components. This interplay includes such activities as: gut microbiota biotransforming HM chemicals into metabolites that harbor different bioavailability and bioactivity/toxicity from their precursors; HM chemicals improving the composition of gut microbiota, consequently ameliorating its dysfunction as well as associated pathological conditions; and gut microbiota mediating the interactions (synergistic and antagonistic) between the multiple chemicals in HMs. More advanced experimental designs are recommended for future study, such as overall chemical characterization of gut microbiota-metabolized HMs, direct microbial analysis of HM-targeted gut microbiota, and precise gut microbiota research model development. The outcomes of such research can further elucidate the interactions between HMs and gut microbiota, thereby opening a new window for defining the scientific basis of HMs and for guiding HM-based drug discovery.
REFERENCES
- 1 WHO. General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organization 2000; 1–71.
- 2Qiu J. Traditional medicine—A culture in the balance. Nature 2007; 448(7150): 126–128.
- 3Qiu J. “Back to the future” for Chinese herbal medicines. Nat Rev Drug Discov 2007; 6(7): 506–507.
- 4Jaiswal Y, Liang Z, Zhao Z. Botanical drugs in Ayurveda and traditional Chinese medicine. J Ethnopharmacol 2016; 194: 245–259.
- 5Azaizeh H, Saad B, Cooper E, Said O. Traditional Arabic and Islamic medicine, a re-emerging health aid. Evid Based Complement Alternat Med 2010; 7(4): 419–424.
- 6 WHO. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. Geneva: World Health Organization; 2004.
- 7Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014; 4: Article Number:177:1–10.
- 8Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov 2016; 15: 473–484.
- 9Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Brit J Pharmacol 2011; 162(6): 1239–1249.
- 10Tu YY. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011; 17(10): 1217–1220.
- 11Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 2015; 14(2): 111–129.
- 12Hou SX. Theory and Practice for Design of Modern Chinese Medicine Preparation. Beijing: People's Medical Publishing House; 2010.
- 13Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008; 105(12): 4826–4831.
- 14Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016; 79(3): 629–661.
- 15Zhang M, Long Y, Sun Y, Wang YK, Li QA, Wu HJ, Guo ZJ, Li YH, Niu YB, Li C, Liu L, Mei QB. Evidence for the complementary and synergistic effects of the three-alkaloid combination regimen containing berberine, hypaconitine and skimmianine on the ulcerative colitis rats induced by trinitrobenzene-sulfonic acid. Eur J Pharmacol 2011; 651(1–3): 187–196.
- 16Kono T, Shimada M, Yamamoto M, Kaneko A, Oomiya Y, Kubota K, Kase Y, Lee K, Uezono Y. Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: Analysis of daikenchuto. Front Pharmacol 2015; 6: Article Number: 159: 1–7.
- 17Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010; 90(3): 859–904.
- 18Li HK, Zhou MM, Zhao AH, Jia W. Traditional Chinese medicine: Balancing the gut ecosystem. Phytother Res 2009; 23(9): 1332–1335.
- 19Chen F, Wen Q, Jiang J, Li HL, Tan YF, Li YH, Zeng NK. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J Ethnopharmacol 2016; 179: 253–264.
- 20Jia W, Li HK, Zhao LP, Nicholson JK. Gut microbiota: A potential new territory for drug targeting. Nat Rev Drug Discov 2008; 7(2): 123–129.
- 21Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312(5778): 1355–1359.
- 22Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: An integrative view. Cell 2012; 148(6): 1258–1270.
- 23Sommer F, Backhed F. The gut microbiota—Masters of host development and physiology. Nat Rev Microbiol 2013; 11(4): 227–238.
- 24Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489(7415): 242–249.
- 25Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012; 336(6086): 1262–1267.
- 26Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9(5): 313–323.
- 27Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122(1): 107–118.
- 28Bouskra D, Brezillon C, Berard M, Werts C, Varona R, Boneca IG, Eberl G. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008; 456(7221): 507–U534.
- 29Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Berard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Dore J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342(6161): 971–976.
- 30Zeuthen LH, Fink LN, Frokiaer H. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta. Immunology 2008; 123(2): 197–208.
- 31Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5(1): 104–112.
- 32Massacand JC, Kaiser P, Ernst B, Tardivel A, Burki K, Schneider P, Harris NL. Intestinal bacteria condition dendritic cells to promote IgA production. PLoS One 2008; 3(7). Article Number: e2588: 1–9.
- 33Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013; 14(7): 685–690.
- 34Franks I. Microbiota: Gut microbes might promote intestinal angiogenesis. Nat Rev Gastroenterol Hepatol 2013; 10(3):1.
- 35Sharma R, Young C, Neu J. Molecular modulation of intestinal epithelial barrier: Contribution of microbiota. J Biomed Biotechnol 2010; 2010: 305879.
- 36Freitas M, Axelsson LG, Cayuela C, Midtvedt T, Trugnan G. Microbial-host interactions specifically control the glycosylation pattern in intestinal mouse mucosa. Histochem Cell Biol 2002; 118(2): 149–161.
- 37Cryan JF, Dinan TG. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13(10): 701–712.
- 38Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 2004; 558(Pt 1): 263–275.
- 39Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108(38): 16050–16055.
- 40Sternberg EM. Neural regulation of innate immunity: A coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006; 6(4): 318–328.
- 41Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res 2008; 43(2): 164–174.
- 42Thomas RH, Meeking MM, Mepham JR, Tichenoff L, Possmayer F, Liu S, MacFabe DF. The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: Further development of a rodent model of autism spectrum disorders. J Neuroinflammation 2012; 9: Article Number:153:1–18.
- 43Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther 2015; 37(5): 984–995.
- 44Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2015; 3(3): 207–215.
- 45Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490(7418): 55–60.
- 46Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 2016; 12(3): 154–167.
- 47Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016; 13(7): 412–425.
- 48Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, Kroemer G. Cancer and the gut microbiota: An unexpected link. Sci Transl Med 2015; 7(271): 271ps271.
- 49Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9(10): 599–608.
- 50Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11(8): 497–505.
- 51Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: A new clinical frontier. Gut 2016; 65(2): 330–339.
- 52Patel R, DuPont HL. New approaches for bacteriotherapy: Prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis 2015; 60: S108–S121.
- 53Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44(5): 354–360.
- 54Liu JY, Lee KF, Sze CW, Tong Y, Tang SCW, Ng TB, Zhang YB. Intestinal absorption and bioavailability of traditional Chinese medicines: A review of recent experimental progress and implication for quality control. J Pharm Pharmacol 2013; 65(5): 621–633.
- 55Liu HF, Yang JL, Du FF, Gao XM, Ma XT, Huang YH, Xu F, Niu W, Wang FQ, Mao Y, Sun Y, Lu T, Liu CX, Zhang BL, Li C. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 2009; 37(12): 2290–2298.
- 56Laparra JM, Sanz Y. Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 2010; 61(3): 219–225.
- 57El Kaoutari A, Armougom F, Gordon JI, Raoult D, Henrissat B. The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nat Rev Microbiol 2013; 11(7): 497–504.
- 58Kim DH, Kim SY, Park SY, Han MJ. Metabolism of quercitrin by human intestinal bacteria and its relation to some biological activities. Biol Pharm Bull 1999; 22(7): 749–751.
- 59Kawata Y, Hattori M, Akao T, Kobashi K, Namba T. Formation of nitrogen-containing metabolites from geniposide and gardenoside by human intestinal bacteria. Planta Med 1991; 57(6): 536–542.
- 60Kawata Y, Ma CM, Meselhy MR, Nakamura N, Wang H, Hattori M, Namba T, Satoh K, Kuraisi Y. Conversion of aconitine lipoaconitine by human intestinal bacteria and their antinociceptive effects in mice. J Tradit Med 1999; 16(1): 15–23.
- 61Meselhy MR, Kadota S, Tsubono K, Hattori M, Namba T. Biotransformation of shikonin by human intestinal bacteria. Tetrahedron 1994; 50(10): 3081–3098.
- 62Wang RF, Yuan M, Yang XB, Xu W, Yang XW. Intestinal bacterial transformation—A nonnegligible part of Chinese medicine research. J Asian Nat Prod Res 2013; 15(5): 532–549.
- 63Yim JS, Kim YS, Moon SK, Cho KH, Bae HS, Kim JJ, Park EK, Kim DH. Metabolic activities of ginsenoside Rb1, baicalin, glycyrrhizin and geniposide to their bioactive compounds by human intestinal microflora. Biol Pharm Bull 2004; 27(10): 1580–1583.
- 64Li F, Wang DW, Xu P, Wu J, Liu L, Liu XD. Identification of the metabolites of anti-inflammatory compound clematichinenoside AR in rat intestinal microflora. Biomed Chromatogr 2013; 27(12): 1767–1774.
- 65Hein EM, Rose K, Van't Slot G, Friedrich AW, Humpf HU. Deconjugation and degradation of flavonol glycosides by pig cecal microbiota characterized by fluorescence in situ hybridization (FISH). J Agric Food Chem 2008; 56(6): 2281–2290.
- 66Jin JS, Zhao YF, Nakamura N, Akao T, Kakiuchi N, Min BS, Hattori M. Enantioselective dehydroxylation of enterodiol and enterolactone precursors by human intestinal bacteria. Biol Pharm Bull 2007; 30(11): 2113–2119.
- 67Yang L, Akao T, Kobashi K. Purification and characterization of a geniposide-hydrolyzing β-glucosidase from Eubacterium sp a-44, a strict anaerobe from human feces. Biol Pharm Bull 1995; 18(9): 1175–1178.
- 68Akao T. Purification and characterization of glycyrrhetic acid mono-glucuronide β-D-glucuronidase in Eubacterium sp. GLH. Biol Pharm Bull 1999; 22(1): 80–82.
- 69Hattori M, Kawata Y, Inoue K, Shu YZ, Che QM, Namba T, Kobashi K. Transformation of aucubin to new pyridine monoterpene alkaloids, aucubinines A and B, by human intestinal bacteria. Phytother Res 1990; 4(2): 66–70.
- 70Kanaoka M, Akao T, Kobashi K. Metabolism of ginseng saponins, ginsenosides by human intestinal flora. J Tradit Med 1994; 11: 241–245.
- 71Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Drug metabolism: Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 1998; 50(10): 1155–1160.
- 72Bae E-A, Park S-Y, KIM D-H. Constitutive β-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull 2000; 23(12): 1481–1485.
- 73Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997; 63(5): 436–440.
- 74Odani T, Tanizawa H, Takino Y. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins .III. The absorption, distribution and excretion of ginsenoside Rb1 in the rat. Chem Pharm Bull 1983; 31(3): 1059–1066.
- 75Zhu J, Jiang Y, Wu L, Lu T, Xu G, Liu X. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience 2012; 202: 342–351.
- 76Paek IP, Moon Y, Kim J, Ji HY, Kim SA, Sohn DH, Kim JB, Lee HS. Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharm Drug Dispos 2006; 27(1): 39–45.
- 77Ren HC, Sun JG, Wang GJ, A JY, Xie HT, Zha WB, Yan B, Sun FZ, Hao HP, Gu SH, Sheng LS, Shao F, Shi J, Zhou F. Sensitive determination of 20(S)-protopanaxadiol in rat plasma using HPLC-APCI-MS: Application of pharmacokinetic study in rats. J Pharm Biomed Anal 2008; 48(5): 1476–1480.
- 78Lee HU, Bae EA, Han MJ, Kim NJ, Kim DH. Hepatoprotective effect of ginsenoside Rb1 and compound K on tert-butyl hydroperoxide-induced liver injury. Liver Int 2005; 25(5): 1069–1073.
- 79Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—The key step of inflammation. Biochem Pharmacol 2011; 82(3): 278–286.
- 80Park EK, Shin YW, Lee HU, Kim SS, Lee YC, Lee BY, Kim DH. Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biol Pharm Bull 2005; 28(4): 652–656.
- 81Wang CZ, Du GJ, Zhang ZY, Wen XD, Calway T, Zhen Z, Musch MW, Bissonnette M, Chang EB, Yuan CS. Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol 2012; 40(6): 1970–1976.
- 82Wakabayashi C, Murakami K, Hasegawa H, Murata J, Saiki I. An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells. Biochem Biophys Res Commun 1998; 246(3): 725–730.
- 83Li W, Liu Y, Zhang JW, Ai CZ, Xiang N, Liu HX, Yang L. Anti-androgen-independent prostate cancer effects of ginsenoside metabolites in vitro: Mechanism and possible structure-activity relationship investigation. Arch Pharm Res 2009; 32(1): 49–57.
- 84Choo MK, Park EK, Han MJ, Kim DH. Antiallergic activity of ginseng and its ginsenosides. Planta Med 2003; 69(6): 518–522.
- 85Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, Yang L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006; 91(2): 356–364.
- 86Lee SJ, Ko WG, Kim JH, Sung JH, Lee SJ, Moon CK, Lee BH. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol 2000; 60(5): 677–685.
- 87Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, a metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology 2004; 29(5): 860–868.
- 88Bae MY, Cho JH, Choi IS, Park HM, Lee MG, Kim DH, Jang IS. Compound K, a metabolite of ginsenosides, facilitates spontaneous GABA release onto CA3 pyramidal neurons. J Neurochem 2010; 114(4): 1085–1096.
- 89Park EJ, Zhao YZ, Kim J, Sohn DH. A ginsenoside metabolite, 20-O-β;-D-glucopyranosyl-20(S)-protopanaxadiol, triggers apoptosis in activated rat hepatic stellate cells via caspase-3 activation. Planta Med 2006; 72(13): 1250–1253.
- 90Garcia-Munoz C, Vaillant F. Metabolic fate of ellagitannins: Implications for health, and research perspectives for innovative functional foods. Crit Rev Food Sci Nutr 2014; 54(12): 1584–1598.
- 91Gonzalez-Barrio R, Borges G, Mullen W, Crozier A. Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. J Agric Food Chem 2010; 58(7): 3933–3939.
- 92Espín JC, Larrosa M, García-Conesa MT, Tomás-Barberán F. Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: The evidence so far. Evid Based Complement Alternat Med 2013; 2013: Article ID 270418:1–15.
- 93Tomas-Barberan FA, Garcia-Villalba R, Gonzalez-Sarrias A, Selma MV, Espin JC. Ellagic acid metabolism by human gut microbiota: Consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J Agric Food Chem 2014; 62(28): 6535–6538.
- 94Seeram NP, Henning SM, Zhang YJ, Suchard M, Li ZP, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006; 136(10): 2481–2485.
- 95Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 2007; 55(19): 7732–7737.
- 96Piwowarski JP, Kiss AK, Granica S, Moeslinger T. Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages. Mol Nutr Food Res 2015; 59(11): 2168–2177.
- 97Piwowarski JP, Granica S, Zwierzynska M, Stefanska J, Schopohl P, Melzig MF, Kiss AK. Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials. J Ethnopharmacol 2014; 155(1): 801–809.
- 98Stolarczyk M, Piwowarski JP, Granica S, Stefanska J, Naruszewicz M, Kiss AK. Extracts from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion. Phytother Res 2013; 27(12): 1842–1848.
- 99Giorgio C, Mena P, Del Rio D, Brighenti F, Barocelli E, Hassan-Mohamed I, Callegari D, Lodola A, Tognolini M. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res 2015; 59(11): 2155–2167.
- 100Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Felix AA, Williams EG, Jha P, Lo Sasso G, Huzard D, Aebischer P, Sandi C, Rinsch C, Auwerx J. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med 2016; 22(8): 879–888.
- 101Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Lin Y, Chen YC, You XF, Wang Y, Jiang JD. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep 2015; 5: Article Number: 12155:1–15.
- 102Xu J, Lian FM, Zhao LH, Zhao YF, Chen XY, Zhang X, Guo Y, Zhang CH, Zhou Q, Xue ZS, Pang XY, Zhao LP, Tong XL. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J 2015; 9(3): 552–562.
- 103Xiang C, Qiao X, Wang Q, Li R, Miao WJ, Guo DA, Ye M. From single compounds to herbal extract: A strategy to systematically characterize the metabolites of licorice in rats. Drug Metab Dispos 2011; 39(9): 1597–1608.
- 104Wan JY, Liu P, Wang HY, Qi LW, Wang CZ, Li P, Yuan CS. Biotransformation and metabolic profile of American ginseng saponins with human intestinal microflora by liquid chromatography quadrupole time-of-flight mass spectrometry. J Chromatogr A 2013; 1286: 83–92.
- 105Jang SE, Jung IH, Joh EH, Han MJ, Kim DH. Antibiotics attenuate anti-scratching behavioral effect of ginsenoside Re in mice. J Ethnopharmacol 2012; 142(1): 105–112.
- 106Yang XW, Hao MR, Hattori M. Metabolite Analysis for Chemical Constituentes of Traditional Chinese Medicine. Beijing: China Medical Science Press; 2003.
- 107Wang HY, Hua HY, Liu XY, Liu JH, Yu BY. in vitro biotransformation of red ginseng extract by human intestinal microflora: Metabolites identification and metabolic profile elucidation using LC-Q-TOF/MS. J Pharm Biomed Anal 2014; 98: 296–306.
- 108Li N, Wang DD, Ge GB, Wang XL, Liu Y, Yang L. Ginsenoside metabolites inhibit p-glycoprotein in vitro and in situ using three absorption models. Planta Med 2014; 80(4): 290–296.
- 109Tabuchi M, Imamura S, Kawakami Z, Ikarashi Y, Kase Y. The blood-brain barrier permeability of 18 beta-glycyrrhetinic acid, a major metabolite of glycyrrhizin in glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol 2012; 32(7): 1139–1146.
- 110Wang G, Fu H, Ye W, Zheng X, Xiao J, Kang D, Rao T, Shao Y, Xie L, Liang Y. Comprehensive characterization of the in vitro and in vivo metabolites of ziyuglycoside I in rat microsome, intestinal flora, excretion specimen and fresh tissues based on LC-Q-TOF/MS. J Pharm Biomed Anal 2016; 128: 191–200.
- 111Cao WY, Feng B, Cheng LF, Wang Y, Wang J, Wang XJ. The octanol/water distribution coefficients of ardipusilloside-I and its metabolites, and their permeation characteristics across Caco-2 cell monolayer. Chem Cent J 2016; 10: 29–37.
- 112Cao WY, Wang YN, Wang PY, Lei W, Feng B, Wang XJ. Ardipusilloside-I metabolites from human intestinal bacteria and their antitumor activity. Molecules 2015; 20(11): 20569–20581.
- 113Suzuki YA, Murata Y, Inui H, Sugiura M, Nakano Y. Triterpene glycosides of Siraitia grosvenori inhibit rat intestinal maltase and suppress the rise in blood glucose level after a single oral administration of maltose in rats. J Agric Food Chem 2005; 53(8): 2941–2946.
- 114Ha YW, Na YC, Ha IJ, Kim DH, Kim YS. Liquid chromatography/mass spectrometry-based structural analysis of new platycoside metabolites transformed by human intestinal bacteria. J Pharm Biomed Anal 2010; 51(1): 202–209.
- 115Zhang YQ, Zhang Y, Zhang KS, Ma GJ, Zhang MC, Xie JB. Degradation kinetics of jujuboside B by rat intestinal fora in vitro with an RRLC-MS-MS method. J Chromatogr Sci 2014; 52(7): 691–696.
- 116Zhou RN, Song YL, Ruan JQ, Wang YT, Yan R. Pharmacokinetic evidence on the contribution of intestinal bacterial conversion to beneficial effects of astragaloside IV, a marker compound of Astragali Radix, in traditional oral use of the herb. Drug Metab Pharmacokinet 2012; 27(6): 586–597.
- 117Lim SM, Jeong JJ, Kang GD, Kim KA, Choi HS, Kim DH. Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance. Int Immunopharmacol 2015; 25(2): 493–503.
- 118Jung IH, Jang SE, Joh EH, Chung J, Han MJ, Kim DH. Lancemaside A isolated from Codonopsis lanceolata and its metabolite echinocystic acid ameliorate scopolamine-induced memory and learning deficits in mice. Phytomedicine 2012; 20(1): 84–88.
- 119Kim YS, Kim JJ, Cho KH, Jung WS, Moon SK, Park EK, Kim DH. Biotransformation of ginsenoside Rbl, crocin, amygdalin, geniposide, puerarin, ginsenoside Re, hesperidin, poncirin, glycyrrhizin, and baicalin by human fecal microflora and its relation to cytotoxicity against tumor cells. J Microbiol Biotechnol 2008; 18(6): 1109–1114.
- 120Yang L, Xu SJ, Liu CJ, Su ZJ. In vivo metabolism study of ginsenoside Re in rat using high-performance liquid chromatography coupled with tandem mass spectrometry. Anal Bioanal Chem 2009; 395(5): 1441–1451.
- 121Xu F, Li DP, Huang ZC, Lu FL, Wang L, Huang YL, Wang RF, Liu GX, Shang MY, Cai SQ. Exploring in vitro, in vivo metabolism of mogroside V and distribution of its metabolites in rats by HPLC-ESI-IT-TOF-MS(n). J Pharm Biomed Anal 2015; 115: 418–430.
- 122Griffiths LA, Smith GE. Metabolism of apigenin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem J 1972; 128(4): 901–911.
- 123Bang SH, Hyun YJ, Shim J, Hong SW, Kim DH. Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing α-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol 2015; 25(1): 18–25.
- 124Du LY, Zhao M, Xu J, Qian DW, Jiang S, Shang EX, Guo JM, Liu P, Su SL, Duan JA, Leng XJ. Identification of the metabolites of myricitrin produced by human intestinal bacteria in vitro using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Expert Opin Drug Metab Toxicol 2014; 10(7): 921–931.
- 125Zhao M, Xu J, Qian DW, Guo JM, Jiang S, Shang EX, Duan JA. Identification of astilbin metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. Biomed Chromatogr 2014; 28(7): 1024–1029.
- 126Hattori M, Shu YZ, Elsedawy AI, Namba T, Kobashi K, Tomimori T. Metabolism of homoorientin by human intestinal bacteria. J Nat Prod 1988; 51(5): 874–878.
- 127Lou Y, Zheng JQ, Wang BH, Zhang XG, Zhang X, Zeng S. Metabolites characterization of chamaechromone in vivo and in vitro by using ultra-performance liquid chromatography/Xevo G2 quadrupole time-of-flight tandem mass spectrometry. J Ethnopharmacol 2014; 151(1): 242–252.
- 128Yang J, Qian DW, Guo JM, Jiang S, Shang EX, Duan JA, Xu J. Identification of the major metabolites of hyperoside produced by the human intestinal bacteria using the ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry. J Ethnopharmacol 2013; 147(1): 174–179.
- 129Xue CF, Jiang S, Guo JM, Qian DW, Duan JA, Shang EX. Screening for in vitro metabolites of Abelmoschus manihot extract in intestinal bacteria by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B 2011; 879(32): 3901–3908.
- 130Lu XY, Sun DL, Chen ZJ, Chen T, Li LP, Xu ZH, Jiang HD, Zeng S. Relative contribution of small and large intestine to deglycosylation and absorption of flavonoids from Chrysanthemun morifolium extract. J Agric Food Chem 2010; 58(19): 10661–10667.
- 131Cai Y, Li S, Li T, Zhou R, Wai AT, Yan R. Oral pharmacokinetics of baicalin, wogonoside, oroxylin A 7-O-β-d-glucuronide and their aglycones from an aqueous extract of Scutellariae Radix in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1026: 124–133.
- 132Kang GD, Kim DH. Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance. J Ethnopharmacol 2016; 189: 175–185.
- 133Wang CZ, Zhang CF, Chen LN, Anderson S, Lu F, Yuan CS. Colon cancer chemopreventive effects of baicalein, an active enteric microbiome metabolite from baicalin. Int J Oncol 2015; 47(5): 1749–1758.
- 134Zolnierczyk AK, Maczka WK, Grabarczyk M, Winska K, Wozniak E, Aniol M. Isoxanthohumol—Biologically active hop flavonoid. Fitoterapia 2015; 103: 71–82.
- 135Xing SH, Wang MY, Peng Y, Chen DF, Li XB. Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots. J Ethnopharmacol 2014; 152(1): 183–189.
- 136Bae HS, Kim YS, Cho KH, Lee KS, Kim JJ, Lee HU, Kim DH. Hepatoprotective activity of Reduohanxiao-tang (Yuldahanso-tang) is related to the inhibition of β-glucuronidase. Am J Chin Med 2003; 31(1): 111–117.
- 137Takagaki A, Nanjo F. Biotransformation of (-)-epicatechin, (+)-epicatechin, (-)-catechin, and (+)-catechin by intestinal bacteria involved in isoflavone metabolism. Biosci Biotechnol Biochem 2015; 80(1): 199–202.
- 138Ruan JQ, Li S, Li YP, Wu WJ, Lee SMY, Yan R. The presystemic interplay between gut microbiota and orally administered calycosin-7-O-β-D-glucoside. Drug Metab Dispos 2015; 43(10): 1601–1611.
- 139Wu S, Xu W, Wang FR, Yang XW. Study of the biotransformation of tongmai formula by human intestinal flora and its intestinal permeability across the Caco-2 cell monolayer. Molecules 2015; 20(10): 18704–18716.
- 140Decroos K, Vanhemmens S, Cattoir S, Boon N, Verstraete W. Isolation and characterisation of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions. Arch Microbiol 2005; 183(1): 45–55.
- 141Minamida K, Tanaka M, Abe A, Sone T, Tomita F, Hara H, Asano K. Production of equol from daidzein by gram-positive rod-shaped bacterium isolated from rat intestine. J Biosci Bioeng 2006; 102(3): 247–250.
- 142Wang XL, Hur HG, Lee JH, Kim KT, Kim SI. Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium. Appl Environ Microbiol 2005; 71(1): 214–219.
- 143Hur HG, Beger RD, Heinze TM, Lay JO, Jr, Freeman JP, Dore J, Rafii F. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. Arch Microbiol 2002; 178(1): 8–12.
- 144Hattori M, Shu YZ, Shimizu M, Hayashi T, Morita N, Kobashi K, Xu GJ, Namba T. Metabolism of paeoniflorin and related-compounds by human intestinal bacteria. Chem Pharm Bull 1985; 33(9): 3838–3846.
- 145Yang L, Akao T, Kobashi K. Purification and characterization of a geniposide-hydrolyzing. β-giucosidase from Eubacterium sp. a-44, a strict anaerobe from human feces. Biol Pharm Bull 1995; 18(9): 1175–1178.
- 146Akao T, Kobashi K, Aburada M. Enzymatic studies on the animal and intestinal bacterial metabolism of geniposide. Biol Pharm Bull 1994; 17(12): 1573–1576.
- 147Yokoyama Y, Nagino M. Current scenario for the hepatoprotective effects of Inchinkoto, a traditional herbal medicine, and its clinical application in liver surgery: A review. Hepatol Res 2014; 44(4): 384–394.
- 148Inao M, Mochida S, Matsui A, Eguchi Y, Yulutuz Y, Wang YH, Naiki K, Kakinuma T, Fujimori K, Nagoshi S, Fujiwara K. Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis. J Hepatol 2004; 41(4): 584–591.
- 149Li XN, Huo CH, Wang Q, Zhang XW, Sheng XN, Zhang LT. Microbial metabolism of loganin by intestinal bacteria and identification of new metabolites in rat. Biomed Chromatogr 2008; 22(4): 367–373.
- 150Zhao M, Du L, Tao J, Qian D, Guo J, Jiang S, Shang EX, Duan JA, Wu C. Ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry for rapid analysis of the metabolites of morroniside produced by human intestinal bacteria. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 976–977: 61–67.
- 151Tao JH, Zhao M, Wang DG, Yang C, Du LY, Qiu WQ, Jiang S. Biotransformation and metabolic profile of catalpol with human intestinal microflora by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1009–1010: 163–169.
- 152Elsedawy AI, Hattori M, Kobashi K, Namba T. Metabolism of gentiopicroside (gentiopicrin) by human intestinal bacteria. Chem Pharm Bull 1989; 37(9): 2435–2437.
- 153Shu YZ, Hattori M, Akao T, Kobashi K, Kagei K, Fukuyama K, Tsukihara T, Namba T. Metabolism of paeoniflorin and related compounds by human intestinal bacteria. II. Structures of 7S- and 7R-paeonimetabolines I and II formed by Bacteroides fragilis and Lactobacillus brevis. Chem Pharm Bull 1987; 35(9): 3726–3733.
- 154Elsedawy AI, Shu YZ, Hattori M, Kobashi K, Namba T. Metabolism of swertiamarin from Swertia japonica by human intestinal bacteria. Planta Med 1989; 55(2): 147–150.
- 155Li J, Zhang LA, Jiang ZZ, Shu B, Li F, Bao QL, Zhang LY. Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells. Toxicol In Vitro 2010; 24(4): 1092–1097.
- 156Zhang M, Peng CS, Li XB. In vivo and in vitro metabolites from the main diester and monoester diterpenoid alkaloids in a traditional Chinese herb, the Aconitum species. Evid Based Complement Alternat Med 2015; 2015: Article ID 252434:1–23.
- 157Meselhy MR, Nishimoto E, Akao T, Hattori M. Human intestinal Bacteroides spp. RHEIN-I and RHEIN-II capable of transforming rhein to rheinanthrone, induce rhein-dependent diarrhea in rats. J Tradit Med 2001; 18(4): 169–176.
- 158Dewitte P, Vanhoestenberghe A, Eyssen H. in vitro reduction of rhein anthraquinone to rhein anthrone by rat cecal microflora and some intestinal bacterial strains. Biopharm Drug Dispos 1992; 13(4): 243–253.
- 159Kobashi K, Nishimura T, Kusaka M, Hattori M, Namba T. Metabolism of sennosides by human intestinal bacteria. Planta Med 1980; 40(3): 225–236.
- 160Hattori M, Sakamoto T, Endo Y, Kakiuchi N, Kobashi K, Mizuno T, Namba T. Metabolism of magnolol from Magnoliae Cortex. I. Application of liquid chromatography-mass spectrometry to the analysis of metabolites of magnolol in rats. Chem Pharm Bull 1984; 32(12): 5010–5017.
- 161Wang LQ, Meselhy MR, Li Y, Qin GW, Hattori M. Human intestinal bacteria capable of transforming secoisolariciresinol diglucoside to mammalian lignans, enterodiol and enterolactone. Chem Pharm Bull 2000; 48(11): 1606–1610.
- 162Heinonen S, Nurmi T, Liukkonen K, Poutanen K, Wahala K, Deyama T, Nishibe S, Adlercreutz H. in vitro metabolism of plant lignans: New precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001; 49(7): 3178–3186.
- 163Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 1999; 202(1–2): 91–100.
- 164Prasad K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol 2000; 9(4): 220–225.
- 165Zhang H, Zhao Z, Wang T, Wang Y, Cui X, Zhang H, Fang ZZ. Inhibition of UDP-glucuronosyltransferase (UGT) isoforms by arctiin and arctigenin. Phytother Res 2016; 30(7): 1189–1196.
- 166Liu MY, Li M, Wang XL, Liu P, Hao QH, Yu XM. Study on human intestinal bacterium Blautia sp AUH-JLD56 for the conversion of arctigenin to (-)-3′-desmethylarctigenin. J Agric Food Chem 2013; 61(49): 12060–12065.
- 167Wu X, Yang Y, Dou YN, Ye J, Bian DF, Wei ZF, Tong B, Kong LY, Xia YF, Dai Y. Arctigenin but not arctiin acts as the major effective constituent of Arctium lappa L. fruit for attenuating colonic inflammatory response induced by dextran sulfate sodium in mice. Int Immunopharmacol 2014; 23(2): 505–515.
- 168Lagkouvardos I, Kläring K, Heinzmann SS, Platz S, Scholz B, Engel KH, Schmitt-Kopplin P, Haller D, Rohn S, Skurk T. Gut metabolites and bacterial community networks during a pilot intervention study with flaxseeds in healthy adult men. Mol Nutr Food Res 2015; 59(8): 1614–1628.
- 169Piwowarski JP, Granica S, Kiss AK. Influence of gut microbiota-derived ellagitannins' metabolites urolithins on pro-inflammatory activities of human neutrophils. Planta Med 2014; 80(11): 887–895.
- 170Fu J, Ma JY, Zhang XF, Wang Y, Feng R, Chen YC, Tan XS, Zhang YY, Sun YP, Zhou Y, Ma C, He CY, Zhao ZX, Du XW. Identification of metabolites of FR429, a potential antitumor ellagitannin, transformed by rat intestinal bacteria in vitro, based on liquid chromatography-ion trap-time of flight mass spectrometry analysis. J Pharm Biomed Anal 2012; 71: 162–167.
- 171Olennikov DN, Kashchenko NI, Chirikova NK. in vitro bioaccessibility, human gut microbiota metabolites and hepatoprotective potential of chebulic ellagitannins: a case of padma hepatenr formulation. Nutrients 2015; 7(10): 8456–8477.
- 172Selma MV, Beltran D, Garcia-Villalba R, Espin JC, Tomas-Barberan FA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct 2014; 5(8): 1779–1784.
- 173Selma MV, Tomas-Barberan FA, Beltran D, Garcia-Villalba R, Espin JC. Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. Int J Syst Evol Microbiol 2014; 64(Pt 7): 2346–2352.
- 174Ou K, Sarnoski P, Schneider KR, Song K, Khoo C, Gu L. Microbial catabolism of procyanidins by human gut microbiota. Mol Nutr Food Res 2014; 58(11): 2196–2205.
- 175Duweler KG, Rohdewald P. Urinary metabolites of French maritime pine bark extract in humans. Pharmazie 2000; 55(5): 364–368.
- 176Appeldoorn MM, Vincken JP, Aura AM, Hollman PCH, Gruppen H. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-γ-valerolactone as the major metabolites. J Agric Food Chem 2009; 57(3): 1084–1092.
- 177van Duynhoven J, Vaughan EE, van Dorsten F, Gomez-Roldan V, de Vos R, Vervoort J, van der Hooft JJ, Roger L, Draijer R, Jacobs DM. Interactions of black tea polyphenols with human gut microbiota: Implications for gut and cardiovascular health. Am J Clin Nutr 2013; 98(6 Suppl): 1631S–1641S.
- 178Stoupi S, Williamson G, Drynan JW, Barron D, Clifford MN. A comparison of the in vitro biotransformation of (-)-epicatechin and procyanidin B2 by human faecal microbiota. Mol Nutr Food Res 2010; 54(6): 747–759.
- 179Deprez S, Brezillon C, Rabot S, Philippe C, Mila I, Lapierre C, Scalbert A. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. J Nutr 2000; 130(11): 2733–2738.
- 180Wang LQ, Meselhy MR, Li Y, Nakamura N, Min BS, Qin GW, Hattori M. The heterocyclic ring fission and dehydroxylation of catechins and related compounds by Eubacterium sp. strain SDG-2, a human intestinal bacterium. Chem Pharm Bull 2001; 49(12): 1640–1643.
- 181Selma MV, Espin JC, Tomas-Barberan FA. Interaction between phenolics and gut microbiota: Role in human health. J Agric Food Chem 2009; 57(15): 6485–6501.
- 182Zhang M, Peng CS, Li XB. In vivo and in vitro metabolites from the main diester and monoester diterpenoid alkaloids in a traditional Chinese herb, the Aconitum species. Evid Based Complement Alternat Med 2015;2015: Article ID 252434:1–23.
- 183Yang HY, Chen PC, Wang JD. Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: A review from epidemiologic observations to causal inference. Biomed Res Int 2014;2014: Article ID 569325:1–9.
- 184Balachandran P, Wei F, Lin RC, Khan IA, Pasco DS. Structure activity relationships of aristolochic acid analogues: Toxicity in cultured renal epithelial cells. Kidney Int 2005; 67(5): 1797–1805.
- 185Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, O'Neal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, Frye SV, Zamboni WC, Pepe-Ranney C, Mani S, Kelly L, Redinbo MR. Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem Biol 2015; 22(9): 1238–1249.
- 186Zheng Y, Yang G, Zhao ZH, Guo T, Shi HM, Zhou YF, Sun L. Structural analysis of ginseng polysaccharides extracted by EDTA solution. RSC Adv 2016; 6(4): 2724–2730.
- 187Jin ML, Zhao K, Huang QS, Xu CL, Shang P. Isolation, structure and bioactivities of the polysaccharides from Angelica sinensis (Oliv.) Diels: A review. Carbohyd Polym 2012; 89(3): 713–722.
- 188Xu J, Han QB, Li SL, Chen XJ, Wang XN, Zhao ZZ, Chen HB. Chemistry, bioactivity and quality control of Dendrobium, a commonly used tonic herb in traditional Chinese medicine. Phytochem Rev 2013; 12(2): 341–367.
- 189Zhang RX, Li MX, Jia ZP. Rehmannia glutinosa: Review of botany, chemistry and pharmacology. J Ethnopharmacol 2008; 117(2): 199–214.
- 190Li SP, Wu DT, Lv GP, Zhao J. Carbohydrates analysis in herbal glycomics. Trend Anal Chem 2013; 52: 155–169.
- 191Cantarel BL, Lombard V, Henrissat B. Complex carbohydrate utilization by the healthy human microbiome. PLoS One 2012; 7(6): Article Number: e28742:1–10.
- 192Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: Stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Brit J Nutr 2009; 101(4): 541–550.
- 193Cummings JH. Cellulose and the human gut. Gut 1984; 25(8): 805–810.
- 194Upadhyaya B, McCormack L, Fardin-Kia AR, Juenemann R, Nichenametla S, Clapper J, Specker B, Dey M. Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic functions. Sci Rep 2016; 6: Article Number: 28797:1–12.
- 195Dongowski G, Lorenz A, Anger H. Degradation of pectins with different degrees of esterification by Bacteroides thetaiotaomicron isolated from human gut flora. Appl Environ Microbiol 2000; 66(4): 1321–1327.
- 196Sabater-Molina M, Larque E, Torrella F, Zamora S. Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem 2009; 65(3): 315–328.
- 197Martens EC, Lowe EC, Chiang H, Pudlo NA, Wu M, McNulty NP, Abbott DW, Henrissat B, Gilbert HJ, Bolam DN, Gordon JI. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PLoS Biol 2011; 9(12): Article Number: e1001221:1–16.
- 198Foley MH, Cockburn DW, Koropatkin NM. The Sus operon: A model system for starch uptake by the human gut Bacteroidetes. Cell Mol Life Sci 2016; 73(14): 2603–2617.
- 199Heinken A, Khan MT, Paglia G, Rodionov DA, Harmsen HJM, Thiele I. Functional metabolic map of Faecalibacterium prausnitzii, a beneficial human gut microbe. J Bacteriol 2014; 196(18): 3289–3302.
- 200Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, Shah N, Wang CY, Magrini V, Wilson RK, Cantarel BL, Coutinho PM, Henrissat B, Crock LW, Russell A, Verberkmoes NC, Hettich RL, Gordon JI. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA 2009; 106(14): 5859–5864.
- 201Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell 2016; 165(6): 1332–1345.
- 202Rombeau JL, Kripke SA. Metabolic and intestinal effects of short-chain fatty acids. J Parenter Enteral Nutr 1990; 14(5 Suppl): 181S–185S.
- 203Iwanaga T, Takebe K, Kato I, Karaki S, Kuwahara A. Cellular expression of monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat, and humans, with special reference to slc5a8. Biomed Res 2006; 27(5): 243–254.
- 204Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol 2014; 121: 91–119.
- 205Kendrick SF, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones DE, Day CP. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology 2010; 51(6): 1988–1997.
- 206Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, Kotani J. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res 2008; 28(5): 321–328.
- 207Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 2011; 22(9): 849–855.
- 208Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL, Hancock WW. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136(3): 348–363.
- 209Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009; 459(7245): 356–363.
- 210Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, Gordon JI. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008; 105(43): 16767–16772.
- 211Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61(2): 364–371.
- 212Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341(6145): 569–573.
- 213Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: The role of butyrate on colonic function. Aliment Pharm Ther 2008; 27(2): 104–119.
- 214Ohata A, Usami M, Miyoshi M. Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. Nutrition 2005; 21(7–8): 838–847.
- 215Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 2008; 59(Suppl 2): 251–262.
- 216Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015; 11(10): 577–591.
- 217Vinolo MAR, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly-Y M, Stephens L, Hawkins PT, Curi R. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One 2011; 6(6): Article Number: e21205:1–10.
- 218Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 2011; 3(10): 858–876.
- 219Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 2006; 78(21): 2419–2425.
- 220Schauber J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W, Melcher R, Agerberth B, Luhrs H, Gudmundsson GH. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: Relevance of signalling pathways. Gut 2003; 52(5): 735–741.
- 221Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 2012; 10(5): 323–335.
- 222Cockburn DW, Koropatkin NM. Polysaccharide degradation by the intestinal microbiota and its influence on human health and disease. J Mol Biol 2016;428(16):3230–3252.
- 223Hu DJ, Cheong KL, Zhao J, Li SP. Chromatography in characterization of polysaccharides from medicinal plants and fungi. J Sep Sci 2013; 36(1): 1–19.
- 224Zong AZ, Cao HZ, Wang FS. Anticancer polysaccharides from natural resources: A review of recent research. Carbohyd Polym 2012; 90(4): 1395–1410.
- 225Schepetkin IA, Quinn MT. Botanical polysaccharides: Macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 2006; 6(3): 317–333.
- 226Kato M, Ishige A, Anjiki N, Yamamoto M, Irie Y, Taniyama M, Kibe R, Oka J, Benno Y, Watanabe K. Effect of herbal medicine Juzentaihoto on hepatic and intestinal heat shock gene expression requires intestinal microflora in mouse. World J Gastroenterol 2007; 13(16): 2289–2297.
- 227Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, Ojcius DM, Tseng SF, Wu TR, Chen YYM, Young JD, Lai HC. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun 2015; 6: Article Number: 7489:1–17.
- 228Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect 2015; 17(3): 173–183.
- 229Fernández-García L, Blasco L, Lopez M, Bou G, García-Contreras R, Wood T, Tomas M. Toxin-antitoxin systems in clinical pathogens. Toxins 2016; 8(7): 227.
- 230Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2(2): 123–140.
- 231Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol 2010; 8(3): 207–217.
- 232Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 2013; 26(4): 822–880.
- 233Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol 2008; 85(1): 11–19.
- 234Bollenbach T. Antimicrobial interactions: Mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol 2015; 27: 1–9.
- 235Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006; 119(6): S3–S10.
- 236Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, Ausubel FM. Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci USA 2006; 103(27): 10414–10419.
- 237de Servi B, Ranzini F, Pique N. Effect of Utipro (R) (containing gelatin-xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: Results of an in vitro study. Future Microbiol 2016; 11(5): 651–658.
- 238Voravuthikunchai SP, Suwalak S, Mitranan W. Ellagitannin from Quercus infectoria eradicates intestinal colonization and prevents renal injuries in mice infected with Escherichia coli O157: H7. J Med Microbiol 2012; 61(10): 1366–1372.
- 239Marcial G, Sendker J, Brandt S, de Lampasona MP, Catalan CAN, de Valdez GF, Hensel A. Gastroprotection as an example: Antiadhesion against Helicobacter pylori, anti-inflammatory and antioxidant activities of aqueous extracts from the aerial parts of Lippia integrifolia Hieron. J Ethnopharmacol 2014; 155(2): 1125–1133.
- 240Hamasaki N, Ishii E, Tominaga K, Tezuka Y, Nagaoka T, Kadota S, Kuroki T, Yano I. Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro. Microbiol Immunol 2000; 44(1): 9–15.
- 241Cwikla C, Schmidt K, Matthias A, Bone KM, Lehmann R, Tiralongo E. Investigations into the antibacterial activities of phytotherapeutics against Helicobacter pylori and Campylobacter jejuni. Phytother Res 2010; 24(5): 649–656.
- 242Rigano D, Formisano C, Basile A, Lavitola A, Senatore F, Rosselli S, Brtmo M. Antibacterial activity of flavonoids and phenylpropanoids from Marrubium globosum ssp libanoticum. Phytother Res 2007; 21(4): 395–397.
- 243Lee MH, Kwon HA, Kwon DY, Park H, Sohn DH, Kim YC, Eo SK, Kang HY, Kim SW, Lee JH. Antibacterial activity of medicinal herb extracts against Salmonella. Int J Food Microbiol 2006; 111(3): 270–275.
- 244Natarajan D, Britto SJ, Srinivasan K, Nagamurugan N, Mohanasundari C, Perumal G. Anti-bacterial activity of Euphorbia fusiformis—A rare medicinal herb. J Ethnopharmacol 2005; 102(1): 123–126.
- 245Ndhlala AR, Amoo SO, Stafford GI, Finnie JF, Van Staden J. Antimicrobial, anti-inflammatory and mutagenic investigation of the South African tree aloe (Aloe barberae). J Ethnopharmacol 2009; 124(3): 404–408.
- 246Tekwu EM, Pieme AC, Beng VP. Investigations of antimicrobial activity of some Cameroonian medicinal plant extracts against bacteria and yeast with gastrointestinal relevance. J Ethnopharmacol 2012; 142(1): 265–273.
- 247Bartfay WJ, Bartfay E, Johnson JG. Gram-negative and gram-positive antibacterial properties of the whole plant extract of willow herb (Epilobium angustifolium). Biol Res Nurs 2012; 14(1): 85–89.
- 248Guo MZ, Ding S, Zhao CH, Gu XX, He XY, Huang KL, Luo YB, Liang ZH, Tian HT, Xu WT. Red Ginseng and Semen Coicis can improve the structure of gut microbiota and relieve the symptoms of ulcerative colitis. J Ethnopharmacol 2015; 162: 7–13.
- 249Zeng YQ, Dai ZH, Lu FH, Lu ZY, Liu XS, Chen C, Qu PH, Li DC, Hua ZS, Qu YN, Zou C. Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease. Oncotarget 2016; 7(14): 17468–17478.
- 250Petit L, Gibert M, Popoff MR. Clostridium perfringens: Toxinotype and genotype. Trends Microbiol 1999; 7(3): 104–110.
- 251Putker F, Bos MP, Tommassen J. Transport of lipopolysaccharide to the Gram-negative bacterial cell surface. FEMS Microbiol Rev 2015; 39(6): 985–1002.
- 252Zhang CH, Zhang MH, Wang SY, Han RJ, Cao YF, Hua WY, Mao YJ, Zhang XJ, Pang XY, Wei CC, Zhao GP, Chen Y, Zhao LP. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J 2010; 4(2): 232–241.
- 253Zhao LP. The gut microbiota and obesity: From correlation to causality. Nat Rev Microbiol 2013; 11(9): 639–647.
- 254Fei N, Zhao LP. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 2013; 7(4): 880–884.
- 255Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology—Human gut microbes associated with obesity. Nature 2006; 444(7122): 1022–1023.
- 256Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, Hardt PD. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010; 18(1): 190–195.
- 257Wang JH, Bose S, Kim GC, Hong SU, Kim JH, Kim JE, Kim H. Flos Lonicera ameliorates obesity and associated endotoxemia in rats through modulation of gut permeability and intestinal microbiota. PLoS One 2014; 9(1): e86117:1–14.
- 258Cao Y, Pan Q, Cai W, Shen F, Chen GY, Xu LM, Fan JG. Modulation of gut microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Arch Iran Med 2016; 19(3): 197–203.
- 259Yin XC, Peng JH, Zhao LP, Yu YP, Zhang X, Liu P, Feng Q, Hu YY, Pang XY. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst Appl Microbiol 2013; 36(3): 188–196.
- 260Beerens H, Romond C. Sulfate-reducing anaerobic bacteria in human feces. Am J Clin Nutr 1977; 30(11): 1770–1776.
- 261Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol 2012; 3: Article Number: 448:1–11.
- 262Medani M, Collins D, Docherty NG, Baird AW, O'Connell PR, Winter DC. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. Inflamm Bowel Dis 2011; 17(7): 1620–1625.
- 263Pitcher MCL, Cummings JH. Hydrogen sulphide: A bacterial toxin in ulcerative colitis? Gut 1996; 39(1): 1–4.
- 264Kanazawa K, Konishi F, Mitsuoka T, Terada A, Itoh K, Narushima S, Kumemura M, Kimura H. Factors influencing the development of sigmoid colon cancer—Bacteriologic and biochemical studies. Cancer 1996; 77(8): 1701–1706.
10.1002/(SICI)1097-0142(19960415)77:8+<1701::AID-CNCR18>3.0.CO;2-1 PubMedWeb of Science®Google Scholar
- 265Pitcher MCL, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000; 46(1): 64–72.
- 266Rowan FE, Docherty NG, Coffey JC, O'Connell PR. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Brit J Surg 2009; 96(2): 151–158.
- 267Chen L, Brar MS, Leung FCC, Hsiao WLW. Triterpenoid herbal saponins enhance beneficial bacteria, decrease sulfate-reducing bacteria, modulate inflammatory intestinal microenvironment and exert cancer preventive effects in Apc(Min/+) mice. Oncotarget 2016; 7(21): 31226–31242.
- 268Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A. Prebiotic effects: Metabolic and health benefits. Brit J Nutr 2010; 104: S1–S63.
- 269Sun H, Ni X, Song X, Wen B, Zhou Y, Zou F, Yang M, Peng Z, Zhu H, Zeng Y. Fermented Yupingfeng polysaccharides enhance immunity by improving the foregut microflora and intestinal barrier in weaning rex rabbits. Appl Microbiol Biotechnol 2016;100(18):8105–8120.
- 270Kong X, Zhang Y, Wu X, Yin Y, Tan Z, Feng Y, Yan F, Bo M, Huang R, Li T. Fermentation characterization of Chinese yam polysaccharide and its effects on the gut microbiota of rats. Int J Microbiol 2009; 2009: Article ID 598152:1–13.
- 271Wen J, Teng BX, Yang PR, Chen XJ, Li CH, Jing YP, Wei JS, Zhang CJ. The potential mechanism of Bawei Xileisan in the treatment of dextran sulfate sodium-induced ulcerative colitis in mice. J Ethnopharmacol 2016; 188: 31–38.
- 272Zhang X, Zhao YF, Zhang MH, Pang XY, Xu J, Kang CY, Li M, Zhang CH, Zhang ZG, Zhang YF, Li XY, Ning G, Zhao LP. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012; 7(8): e42529:1–12.
- 273Freile ML, Giannini F, Pucci G, Sturniolo A, Rodero L, Pucci O, Balzareti V, Enriz RD. Antimicrobial activity of aqueous extracts and of berberine isolated from Berberis heterophylla. Fitoterapia 2003; 74(7–8): 702–705.
- 274Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091–1103.
- 275O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O'Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kB activation. PLoS Pathog 2008; 4(8): Article Number: e1000112:1–10.
- 276Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350(6264): 1084–1089.
- 277Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014; 63(5): 727–735.
- 278Yanagibashi T, Hosono A, Oyama A, Tsuda M, Suzuki A, Hachimura S, Takahashi Y, Momose Y, Itoh K, Hirayama K, Takahashi K, Kaminogawa S. IgA production in the large intestine is modulated by a different mechanism than in the small intestine: Bacteroides acidifaciens promotes IgA production in the large intestine by inducing germinal center formation and increasing the number of IgA(+) B cells. Immunobiology 2013; 218(4): 645–651.
- 279Rossi M, Corradini C, Amaretti A, Nicolini M, Pompei A, Zanoni S, Matteuzzi D. Fermentation of fructooligosaccharides and inulin by bifidobacteria: A comparative study of pure and fecal cultures. Appl Environ Microbiol 2005; 71(10): 6150–6158.
- 280Lukovac S, Belzer C, Pellis L, Keijser BJ, de Vos WM, Montijn RC, Roeselers G. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. mBio 2014; 5(4): e01438–01414.
- 281den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54(9): 2325–2340.
- 282Tappenden KA, Albin DM, Bartholome AL, Mangian HF. Glucagon-like peptide-2 and short-chain fatty acids: A new twist to an old story. J Nutr 2003; 133(11): 3717–3720.
- 283Fehervari Z. Fueling IgA production. Nat Immunol 2016; 17(10): 1141.
- 284Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013; 138(1): 1–11.
- 285Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110(22): 9066–9071.
- 286Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLoS One 2013; 8(9): Article Number: e74963:1–15.
- 287Chu HT, Khosravi A, Kusumawardhani IP, Kwon AHK, Vasconcelos AC, Cunha LD, Mayer AE, Shen Y, Wu WL, Kambal A, Targan SR, Xavier RJ, Ernst PB, Green DR, McGovern DPB, Virgin H, Mazmanian SK. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 2016; 352(6289): 1116–1120.
- 288Kim BS, Song MY, Kim H. The anti-obesity effect of Ephedra sinica through modulation of gut microbiota in obese Korean women. J Ethnopharmacol 2014; 152(3): 532–539.
- 289Han K, Bose S, Kim YM, Chin YW, Kim BS, Wang JH, Lee JH, Kim H. Rehmannia glutinosa reduced waist circumferences of Korean obese women possibly through modulation of gut microbiota. Food Funct 2015; 6(8): 2684–2692.
- 290Wang XM, Lu Y, Wu LY, Yu SG, Zhao BX, Hu HY, Wu HG, Bao CH, Liu HR, Wang JH, Yao Y, Hua XG, Guo HY, Shen LR. Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis. World J Gastroenterol 2012; 18(46): 6819–6828.
- 291Liu L, Yuan SF, Long Y, Guo ZJ, Sun Y, Li YH, Niu YB, Li C, Mei QB. Immunomodulation of Rheum tanguticum polysaccharide (RTP) on the immunosuppressive effects of dexamethasone (DEX) on the treatment of colitis in rats induced by 2,4,6-trinitrobenzene sulfonic acid. Int Immunopharmacol 2009; 9(13–14): 1568–1577.
- 292Ko SJ, Han G, Kim SK, Seo JG, Chung WS, Ryu B, Kim J, Yeo I, Lee BJ, Lee JM, Park JW. Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2013; 2013: Article ID 824605:1–10.
- 293Chen L, Tai WCS, Brar MS, Leung FCC, Hsiao WLW. Tumor grafting induces changes of gut microbiota in athymic nude mice in the presence and absence of medicinal Gynostemma saponins. PLoS One 2015; 10(5): Article Number: e0126807:1–18.
- 294Wang J, Ye F, Cheng X, Zhang X, Liu F, Liu G, Ni M, Qiao S, Zhou W, Zhang Y. The effects of LW-AFC on intestinal microbiome in senescence-accelerated mouse prone 8 strain, a mouse model of Alzheimer's disease. J Alzheimers Dis 2016;53(3):907–919.
- 295Zhou SS, Xu J, Zhu H, Wu J, Xu JD, Yan R, Li XY, Liu HH, Duan SM, Wang Z, Chen HB, Shen H, Li SL. Gut microbiota-involved mechanisms in enhancing systemic exposure of ginsenosides by coexisting polysaccharides in ginseng decoction. Sci Rep 2016; 6: Article number: 22474:1–13.
- 296Takayama K, Tsutsumi H, Ishizu T, Okamura N. The influence of rhein 8-O-β-D-glucopyranoside on the purgative action of sennoside A from rhubarb in mice. Biol Pharm Bull 2012; 35(12): 2204–2208.
- 297Hasebe T, Ueno N, Musch MW, Nadimpalli A, Kaneko A, Kaifuchi N, Watanabe J, Yamamoto M, Kono T, Inaba Y. Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K. Pharmacol Res Perspect 2016; 4(1): Article Number: e00215:1–10.
- 298Zuo F, Zhou ZM, Yan MZ, Liu ML, Xiong YL, Zhang Q, Song HY, Ye WH. Metabolism of constituents in Huangqin-Tang, a prescription in traditional Chinese medicine, by human intestinal flora. Biol Pharm Bull 2002; 25(5): 558–563.
- 299Huo T, Fang Y, Zhao L, Xiong Z, Zhang Y, Wang Y, Feng C, Yuan M, Wang S, Chen M. 1HNMR-based metabonomic study of sub-chronic hepatotoxicity induced by realgar. J Ethnopharmacol 2016; 192: 1–9.
- 300Xu WF, Wang HF, Chen G, Li W, Xiang RW, Pei YH. H-1 NMR-based metabonomics study on the toxicity alleviation effect of other traditional Chinese medicines in Niuhuang Jiedu tablet to realgar (As2S2). J Ethnopharmacol 2013; 148(1): 88–98.
- 301Wang XJ, Wang HY, Zhang AH, Lu X, Sun H, Dong H, Wang P. Metabolomics study on the toxicity of aconite root and its processed products using ultraperformance liquid-chromatography/electrospray-ionization synapt high-definition mass spectrometry coupled with pattern recognition approach and ingenuity pathways analysis. J Proteome Res 2012; 11(2): 1284–1301.
- 302Zhang JM, Liao W, He YX, He Y, Yan D, Fu CM. Study on intestinal absorption and pharmacokinetic characterization of diester diterpenoid alkaloids in precipitation derived from Fuzi-Gancao herb-pair decoction for its potential interaction mechanism investigation. J Ethnopharmacol 2013; 147(1): 128–135.
- 303Shen H, Wu J, Di LQ, Zhu LY, Xu J, Yan R, Li SL. Enhancement by Glycyrrhizae Radix of hepatic metabolism of hypaconitine, a major bioactive and toxic component of Aconiti Laterlis Radix, evaluated by HPLC-TQ-MS/MS analysis. Biomed Chromatogr 2013; 27(5): 556–562.
- 304Zhang QY, Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J Chromatogr A 2009; 1216(11): 1954–1969.
- 305Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from Liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol 2009; 125(2): 218–223.
- 306Shang XF, He XR, He XY, Li MX, Zhang RX, Fan PC, Zhang QL, Jia ZP. The genus Scutellaria an ethnopharmacological and phytochemical review. J Ethnopharmacol 2010; 128(2): 279–313.
- 307Shan JJ, Zou JS, Xie T, Kang A, Zhou W, Deng HS, Mao YC, Di LQ, Wang SC. Pharmacokinetics, intestinal absorption and microbial metabolism of single platycodin D in comparison to Platycodi Radix extract. Pharmacogn Mag 2015; 11(44): 750–755.
- 308Shan JJ, Zou JS, Xie T, Kang A, Zhou W, Xu JY, Shen CS, Du LN, Wang SC, Di LQ. Effects of Gancao on pharmacokinetic profiles of platycodin D and deapio-platycodin D in Jiegeng. J Ethnopharmacol 2015; 170: 50–56.
- 309Xu CH, Wang P, Wang Y, Yang Y, Li DH, Li HF, Sun SQ, Wu XZ. Pharmacokinetic comparisons of two different combinations of Shaoyao-Gancao Decoction in rats: Competing mechanisms between paeoniflorin and glycyrrhetinic acid. J Ethnopharmacol 2013; 149(2): 443–452.
- 310Yan DM, Ma BL, Shi R, Wang TM, Ma YM. Involvement of herb-herb interactions in the influences of Radix Scutellaria and Coptis chinensis on the bioavailability of the anthraquinones form Rhei Rhizoma in rats. Eur J Drug Metab Pharmacokinet 2015; 40(1): 103–110.
- 311Shi R, Zhou H, Liu ZM, Ma YM, Wang TM, Liu YY, Wang CH. Influence of Coptis chinensis on pharmacokinetics of flavonoids after oral administration of Radix Scutellariae in rats. Biopharm Drug Dispos 2009; 30(7): 398–410.
- 312Cernakova M, Kostalova D. Antimicrobial activity of berberine—A constituent of Mahonia aquifolium. Folia Microbiol 2002; 47(4): 375–378.
- 313Zhang X, Zhao YF, Xu J, Xue ZS, Zhang MH, Pang XY, Zhang XJ, Zhao LP. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep 2015; 5: Article Number: 14405:1–10.
- 314Yang L, Xu SJ, Liu CJ, Su ZJ. In vivo metabolism study of ginsenoside Re in rat using high-performance liquid chromatography coupled with tandem mass spectrometry. Anal Bioanal Chem 2009; 395(5): 1441–1451.
- 315Ong ES. Extraction methods and chemical standardization of botanicals and herbal preparations. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 812(1–2): 23–33.
- 316Liu CC, Wu YF, Feng GM, Gao XX, Zhou YZ, Hou WJ, Qin XM, Du GH, Tian JS. Plasma-metabolite-biomarkers for the therapeutic response in depressed patients by the traditional Chinese medicine formula Xiaoyaosan: A 1H NMR-based metabolomics approach. J Affect Disord 2015; 185: 156–163.
- 317Zhou YT, Liao QF, Lin MN, Deng XJ, Zhang PT, Yao MC, Zhang L, Xie ZY. Combination of H-1 NMR- and GC-MS-based metabonomics to study on the toxicity of Coptidis Rhizome in rats. PLoS One 2014; 9(2): e88281:1–12.
- 318Shi XH, Xiao CN, Wang YL, Tang HR. Gallic acid intake induces alterations to systems metabolism in rats. J Proteome Res 2013; 12(2): 991–1006.
- 319Dong G, Wang JS, Guo PP, Wei DD, Yang MH, Kong LY. Toxicity assessment of Arisaematis Rhizoma in rats by a H-1 NMR-based metabolomics approach. Mol Biosyst 2015; 11(2): 407–417.
- 320Huang DX, Yang J, Lu XM, Deng Y, Xiong ZL, Li FM. An integrated plasma and urinary metabonomic study using UHPLC-MS: Intervention effects of Epimedium koreanum on “Kidney-Yang Deficiency syndrome” rats. J Pharm Biomed Anal 2013; 76: 200–206.
- 321Chao J, Huo TI, Cheng HY, Tsai JC, Liao JW, Lee MS, Qin XM, Hsieh MT, Pao LH, Peng WH. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. PLoS One 2014; 9(6): Article Number: e96969:1–18.
- 322Huang Y, Bo Y, Wu X, Wang Q, Qin F, Zhao L, Xiong Z. An intergated serum and urinary metabonomic research based on UPLC-MS and therapeutic effects of Gushudan on prednisolone-induced osteoporosis rats. J Chromatogr B 2016; 1027: 119–130.
- 323Lu XM, Xiong ZL, Li JJ, Zheng SN, Huo TG, Li FM. Metabonomic study on “Kidney-Yang Deficiency syndrome” and intervention effects of Rhizoma Drynariae extracts in rats using ultra performance liquid chromatography coupled with mass spectrometry. Talanta 2011; 83(3): 700–708.
- 324Chen MJ, Ni Y, Duan HQ, Qiu YP, Guo CY, Jiao Y, Shi HJ, Su MM, Jia W. Mass spectrometry-based metabolic profiling of rat urine associated with general toxicity induced by the multiglycoside of Tripterygium wilfordii Hook. f. Chem Res Toxicol 2008; 21(2): 288–294.
- 325Phipps AN, Stewart J, Wright B, Wilson ID. Effect of diet on the urinary excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity. Xenobiotica 1998; 28(5): 527–537.
- 326Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, Mitchell SC, Holmes E, McCarthy MI, Scott J, Gauguier D, Nicholson JK. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006; 103(33): 12511–12516.
- 327Epps SV, Petrujkic BT, Sedej I, Krueger NA, Harvey RB, Beier RC, Stanton TB, Phillips TD, Anderson RC, Nisbet DJ. Comparison of anti-Campylobacter activity of free thymol and thymol-β;-D-glucopyranoside in absence or presence of β;-glycoside-hydrolysing gut bacteria. Food Chem 2015; 173: 92–98.
- 328Decroos K, Eeckhaut E, Possemiers S, Verstraete W. Administration of equol-producing bacteria alters the equol production status in the Simulator of the Gastrointestinal Microbial Ecosystem (SHIME). J Nutr 2006; 136(4): 946–952.
- 329Possemiers S, Rabot S, Espin JC, Bruneau A, Philippe C, Gonzalez-Sarrias A, Heyerick A, Tomas-Barberan FA, De Keukeleire D, Verstraete W. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr 2008; 138(7): 1310–1316.
- 330Lee SJ, Bose S, Seo JG, Chung WS, Lim CY, Kim H. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr 2014; 33(6): 973–981.
- 331Zhou W, Wang HD, Zhu XX, Shan JJ, Yin AL, Cai BC, Di LQ. Improvement of intestinal absorption of forsythoside A and chlorogenic acid by different carboxymethyl chitosan and chito-oligosaccharide, application to Flos Lonicerae-Fructus Forsythiae herb couple preparations. PLoS One 2013; 8(5): Article Number: e63348:1–15.
- 332Arai M, Yokosuka O, Fukai K, Kanda T, Kojima H, Kawai S, Imazeki F, Hirasawa H, Saisho H. A case of severe acute hepatitis of unknown etiology treated with the Chinese herbal medicine Inchinko-to. Hepatol Res 2004; 28(3): 161–165.
- 333Liu C, Hu MY, Guo HF, Zhang M, Zhang J, Li F, Zhong ZY, Chen Y, Li Y, Xu P, Li J, Liu L, Liu XD. Combined contribution of increased intestinal permeability and inhibited deglycosylation of ginsenoside Rb1 in the intestinal tract to the enhancement of ginsenoside Rb1 exposure in diabetic rats after oral administration. Drug Metab Dispos 2015; 43(11): 1702–1710.
- 334Xu J, Zhao M, Qian DW, Shang EX, Jiang S, Guo JM, Duan JA, Du LY. Comparative metabolism of Radix Scutellariae extract by intestinal bacteria from normal and type 2 diabetic mice in vitro. J Ethnopharmacol 2014; 153(2): 368–374.
- 335Tang DQ, Yu YY, Zheng XX, Wu J, Li YJ, Wu XW, Du Q, Yin XX. Comparative investigation of in vitro biotransformation of 14 components in Ginkgo biloba extract in normal, diabetes and diabetic nephropathy rat intestinal bacteria matrix. J Pharm Biomed Anal 2014; 100: 1–10.
- 336van Duynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, van Velzen EJJ, Gross G, Roger LC, Possemiers S, Smilde AK, Dore J, Westerhuis JA, Van de Wiele T. Metabolic fate of polyphenols in the human superorganism. Proc Natl Acad Sci USA 2011; 108: 4531–4538.
- 337Kim KA, Jung IH, Park SH, Ahn YT, Huh CS, Kim DH. Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K. PLoS One 2013; 8(4): Article Number: e62409:1–7.
- 338Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415): 220–230.
- 339Alolga RN, Fan Y, Zhang G, Li J, Zhao YJ, Kakila JL, Chen Y, Li P, Qi LW. Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers. Sci Rep 2015; 5: Article Number: 12961:1–11.
- 340Couch RD, Dailey A, Zaidi F, Navarro K, Forsyth CB, Mutlu E, Engen PA, Keshavarzian A. Alcohol induced alterations to the human fecal VOC metabolome. PLoS One 2015; 10(3): Article Number: e0119362:1–24.
- 341Jiang JG. Treatise on Exogenous Febrile Disease ( 1st ed.). Beijing: China Press of Traditional Chinese Medicine; 2004.